Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent
05 janv. 2017 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
04 janv. 2017 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
14 déc. 2016 16h15 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
09 déc. 2016 09h20 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
07 déc. 2016 16h02 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
15 nov. 2016 08h23 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update
09 nov. 2016 07h00 HE
|
Clearside Biomedical, Inc.
Phase 3 Program of Zuprata™ for Macular Edema Associated with Retinal Vein Occlusion to be Initiated in the First Half of 2017 Phase 1/2 Trial for Diabetic Macular Edema to be Initiated by the End...
Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016
08 nov. 2016 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development
08 nov. 2016 07h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
10 oct. 2016 07h00 HE
|
Clearside Biomedical, Inc.
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ...